Company Filing History:
Years Active: 2018-2022
Title: Youngae Lee: Innovator in Antibody Development
Introduction
Youngae Lee is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of three patents to his name, Lee's work focuses on innovative solutions for treating autoimmune diseases and cancer.
Latest Patents
One of Youngae Lee's latest patents is titled "Anti-VISTA antibody and use thereof." This invention relates to an anti-VISTA antibody or an antigen-binding fragment, along with a nucleic acid coding for the antibody, a vector carrying the nucleic acid, and a method for preparing the antibody. The patent also includes a composition for the prevention or treatment of autoimmune diseases, which comprises the same antibody, and a composition for concurrent administration with a PD-1 or PD-L1 antibody.
Another significant patent is the "EGFRvIII antibody and composition comprising same." This disclosure pertains to an antibody that specifically binds to the epidermal growth factor receptor variant III (EGFRvIII). It includes the nucleic acid coding for the antibody, a vector containing the nucleic acid, and a pharmaceutical composition that utilizes the antibody as an active ingredient for treating cancer or tumors.
Career Highlights
Youngae Lee is currently associated with Pharmabcine Inc., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, particularly in the area of antibody therapeutics.
Collaborations
Lee collaborates with notable colleagues, including Weon Sup Lee and Sang Soon Byun. Their combined expertise contributes to the innovative projects at Pharmabcine Inc.
Conclusion
Youngae Lee's contributions to antibody development highlight his role as an influential inventor in biotechnology. His patents reflect a commitment to addressing critical health challenges through innovative solutions.